Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

• By Sue Sutter

Related Content

Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim

Apr 06 2016

Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up

Apr 21 2017

Novel Biologics In US Might Not Start Getting Suffixes Until August

Apr 05 2017

Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

Aug 17 2016

Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain

Mar 03 2017

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions

Jan 24 2017

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals

Feb 05 2017

Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

Jul 20 2016

Related Companies

Samsung Bioepis Co., Ltd.

Johnson & Johnson

Celltrion, Inc.

Hospira, Inc.

Pfizer Inc.

Amgen, Inc.

Johnson & Johnson

Merck & Co., Inc.

Novartis AG

Additional Topics

United States Biosimilars Approvals Regulation BioPharmaceutical Dermatology Inflammation Gastrointestinal

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window